The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.
【저자키워드】 COVID-19, COVID-19 vaccine, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Guillain-barrè syndrome, AstraZeneca vaccine, CSF, Cerebrospinal fluid, ICU, Intensive care unit, Inflammatory demyelinating polyneuropathy, Chronic inflammatory demyelinating polyneuropathy (CIDP), GBS, Guillain- Barré Syndrome, CIDP, Chronic inflammatory demyelinating polyneuropathy, IDP, Inflammatory demyelinating polyneuropathy, IVIG, Intravenous immune globulin, AZ, AstraZeneca Vaccine/ ChAdOx1 nCoV-19 vaccine, ACE2 receptor, Angiotensin-converting enzyme 2 receptor, NCV, nerve conduction velocity,